XTNT Valuation

Xtant Medical Holdings Inc

Add to Watchlist

Advanced Chart

0.879

-0.041(-4.457%)1D

XTNT Relative Valuation

XTNT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XTNT is overvalued; if below, it's undervalued.

Historical Valuation

Xtant Medical Holdings Inc (XTNT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.88 is considered Undervalued compared with the five-year average of -7.59. The fair price of Xtant Medical Holdings Inc (XTNT) is between 1.21 to 2.34 according to relative valuation methord. Compared to the current price of 0.88 USD , Xtant Medical Holdings Inc is Undervalued By 27.42%.

Relative Value

Fair Zone

1.21-2.34

Current Price：0.88

27.42%

Undervalued

-58.63

Trailing

Forward

14.33

EV/EBITDA

Xtant Medical Holdings Inc. (XTNT) has a current EV/EBITDA of 14.33. The 5-year average EV/EBITDA is 21.72. The thresholds are as follows: Strongly Undervalued below -19.07, Undervalued between -19.07 and 1.33, Fairly Valued between 42.11 and 1.33, Overvalued between 42.11 and 62.50, and Strongly Overvalued above 62.50. The current Forward EV/EBITDA of 14.33 falls within the Historic Trend Line -Fairly Valued range.

105.71

EV/EBIT

Xtant Medical Holdings Inc. (XTNT) has a current EV/EBIT of 105.71. The 5-year average EV/EBIT is -10.55. The thresholds are as follows: Strongly Undervalued below -116.06, Undervalued between -116.06 and -63.31, Fairly Valued between 42.21 and -63.31, Overvalued between 42.21 and 94.96, and Strongly Overvalued above 94.96. The current Forward EV/EBIT of 105.71 falls within the Strongly Overvalued range.

0.88

Xtant Medical Holdings Inc. (XTNT) has a current PS of 0.88. The 5-year average PS is 1.05. The thresholds are as follows: Strongly Undervalued below -0.36, Undervalued between -0.36 and 0.34, Fairly Valued between 1.75 and 0.34, Overvalued between 1.75 and 2.46, and Strongly Overvalued above 2.46. The current Forward PS of 0.88 falls within the Historic Trend Line -Fairly Valued range.

15.02

P/OCF

Xtant Medical Holdings Inc. (XTNT) has a current P/OCF of 15.02. The 5-year average P/OCF is 34.67. The thresholds are as follows: Strongly Undervalued below -207.23, Undervalued between -207.23 and -86.28, Fairly Valued between 155.63 and -86.28, Overvalued between 155.63 and 276.58, and Strongly Overvalued above 276.58. The current Forward P/OCF of 15.02 falls within the Historic Trend Line -Fairly Valued range.

19.24

P/FCF

Xtant Medical Holdings Inc. (XTNT) has a current P/FCF of 19.24. The 5-year average P/FCF is -3.86. The thresholds are as follows: Strongly Undervalued below -33.77, Undervalued between -33.77 and -18.81, Fairly Valued between 11.10 and -18.81, Overvalued between 11.10 and 26.05, and Strongly Overvalued above 26.05. The current Forward P/FCF of 19.24 falls within the Overvalued range.

Xtant Medical Holdings Inc (XTNT) has a current Price-to-Book (P/B) ratio of 2.53. Compared to its 3-year average P/B ratio of 2.23 , the current P/B ratio is approximately 13.22% higher. Relative to its 5-year average P/B ratio of 2.72, the current P/B ratio is about -7.05% higher. Xtant Medical Holdings Inc (XTNT) has a Forward Free Cash Flow (FCF) yield of approximately -2.30%. Compared to its 3-year average FCF yield of -12.58%, the current FCF yield is approximately -81.72% lower. Relative to its 5-year average FCF yield of -8.55% , the current FCF yield is about -73.08% lower.

2.53

P/B

Median3y

2.23

Median5y

2.72

-2.30

FCF Yield

Median3y

-12.58

Median5y

-8.55

Competitors Valuation Multiple

The average P/S ratio for XTNT's competitors is 4.08, providing a benchmark for relative valuation. Xtant Medical Holdings Inc Corp (XTNT) exhibits a P/S ratio of 0.88, which is -78.46% above the industry average. Given its robust revenue growth of 18.26%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

XTNT.A

Xtant Medical Holdings Inc

Performance Decomposition

Market capitalization of XTNT increased by 119.87% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -6.09 to -23.11.

The secondary factor is the Revenue Growth, contributed 18.26%to the performance.

Overall, the performance of XTNT in the past 1 year is driven by P/E Change. Which is more unsustainable.

18.26%

29.94M → 35.41M

Revenue Growth

-177.81%

-12.89 → 10.03

Margin Expansion

279.42%

-6.09 → -23.11

P/E Change

119.87%